Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Reported Additional Positive Phase 2 Data Showing Ridinilazole Improved Quality of Life and Microbiome Preservation Compared to Standard of Care
Sydney, Australia, 10 October 2019: Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, is pleased to announce it has raised AU$6,768,444.28 in a placement to institutional, professional and sophisticated investors that will result in 26,032,478 fully paid ordinary shares being issued at AU$0.26 per share
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will attend several upcoming international conferences.
Heidelberg Pharma AG reported on the first nine months of fiscal year 2019 and the Group’s financial figures.
Datavant, the leader in helping healthcare organizations connect and share health data, announced a series of corporate updates.
UCB indicates the deal is part of its strategic growth plan, dubbed the “Accelerate and Expand” phase since 2019.
Global Blood Therapeutics, Inc., announced that on October 1, 2019, the compensation committee of GBT’s board of directors granted 12 new employees options to purchase an aggregate of 24,600 shares of the company’s common stock with a per share exercise price of $46.99 and restricted stock units for an aggregate of 57,050 shares of the company’s common stock.
Innovate Biopharmaceuticals, Inc. and RDD Pharma, Ltd announced that the two companies entered into a definitive merger agreement pursuant to which Innovate agreed to acquire all of the outstanding capital stock of privately-held RDD in exchange for a combination of common and preferred shares.
Oxford start-up developing novel therapeutics based on deep expertise in immune cell regulation
Sareum Holdings plc, the specialised small molecule drug development business, will announce its results for the full year ended 30 June 2019 on Tuesday 15 October.